Form 4: Gilead Sciences CFO Andrew Dickinson Sells 2,500 Shares
SEC Form 4 Filing
Gilead Sciences' Chief Financial Officer, Andrew Dickinson, sold 2,500 shares of common stock at a price of $99.82 per share on May 15, 2025, according to a Form 4 filing with the SEC.
Summary
- Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, sold 2,500 shares of the company's common stock on May 15, 2025.
- The sale was executed at a price of $99.82 per share.
- Following the transaction, Dickinson directly owns 165,674 shares of Gilead Sciences.
- The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting an insider stock sale. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
This is a routine disclosure of insider trading activity. It is common for executives to have pre-arranged trading plans to avoid accusations of trading on inside information.
Key Dates
| Date | Description |
|---|---|
| 2024-08-29 | Date of adoption of Rule 10b5-1 trading plan. |
| 2025-05-15 | Date of stock sale transaction. |
| 2025-05-16 | Date of signature on the Form 4 filing. |
Keywords
Gilead Sciences, Andrew Dickinson, Form 4, SEC Filing, Stock Sale, GILD, Rule 10b5-1, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.